COVAX Update

World Health Organization

COVID-19 vaccine deployment in EMR at a glance, 16 February 2021

World Health Organization

12 countries vaccinating: Number of doses administered



*No information

Doses administered per 100 population



Vaccine emergency use approvals



Countries with emergency use approval



Countries with agreements and vaccinating



HEALTH FOR ALL BY ALL
a call for solidarity and action

Vaccine pipeline for products included in COVAX and /or CEPI R&D candidate, 15 February 2021

World Health Organization

Type of vaccine	Developer /production site	Estimated efficacy	Number of stringent NRA approvals	Timeline WHO EUL (15 Feb 2021)	Secured doses in COVAX Facility 2021
mRNA	Moderna NIAID	**94.1%**	4	End Feb 2021 Additional date to be submitted	-
	BioNTech/Pfizer	**95%**	6	✓31 Dec 2020	40M
	CureVac AG	Phase III	-	-	-
Non repl. viral vector	Oxford / Astra Zeneca (AZ)	**70% (62-90%)**	2	Mar-Apr. 2021 Finalized review of Core data (Non COVAX) Additional nodes in Mar./Apr. (COVAX)	170M
	Oxford / AZ SK Bio	**70% (62-90%)**	-	✓15 Feb 2021	-
	Oxford / AZ SII (Covishield)	**70% (62-90%)**	-	✓15 Feb 2021	550M
	Janssen (Johnson&Johnson)	66% 57%(SA)-72%(US)	-	Assessment not yet started May-June 2021*	500M
Protein subunit	Novavax	50%(SA)-89%(UK)	-	Awaiting decision on the submission	550M
	Clover/GSK/Dynavax	Phase III	-	-	200M
DNA	Inovio/Int. Vaccine Institute/Advaccine	Phase III	-	-	-

SII: Serum Institute of India

HEALTH FOR ALL BY ALL a call for solidarity

NRA: National Regulatory Authorities; EUL: Emergency Use Listing; EOI: Expression of interest; Estimates in bold published in peer review journal * Abridged process relying on European Medicine Agency

Vaccine pipeline for products not yet included in COVAX, 15 Feb 2021

World Health Organization

Type of vaccine	Developer /production site	Estimated efficacy	Number of stringent NRA approvals	Timeline WHO EUL
Inactivated	Sinovac	50%-91%	0	Additional expected end of Feb 21 Earliest March
	CNBG Wuhan / Sinopharm	*79%-86%*	0	-
	CNBG Beijing / Sinopharm	*79%-86%*	0	Earliest Mar. 2021. Assessment in progress
	Bharat institute, India	Phase III	0	-
	IMB/ Chinese Acc. of sciences	Phase III	0	-
	Res. Inst. for biol. safety, Kazakhstan	Phase III	0	-
Non replicating viral vector	Cansino/ Beijing Inst.	65.7%	0	Rolling data starting Apr. 2021
	Gamalea Inst. (SputnikV)	91%	0	Rolling data expected 8 & 15 Feb.
Protein subunit	Zhifei Longcom, China	Phase III	0	**Response to Second EOI sent 29 Jan 21 Additional information requested**
	COVAXX	Phase III	0	-
Virus like particles	Medicago Inc	Phase III	0	-
DNA	Zydus Cadila	Phase III	0	-
	AnGes/Takara/Osaka U	Phase III	0	-

Italic denotes vaccines with trials in some EMR countries

Israel

- Israel's largest healthcare provider reported a 94% reduction in the rate of symptomatic infection and a 92% decrease in the rate of serious illness in 600,000 people who received two doses of the Pfizer's vaccine
  - No published study yet
- Previous study : Approximately 49% drop in number of cases, 36% drop in COVID-19 related hospitalizations and 29% drop in critically ill patients compared to 21 days ago
- Previous study : Effectiveness of **the first dose of BNT162b2 vaccine 51% 13-24 days after immunization**

England

- An Oxford University study (Center for Evidence Based Medicine) has found that **since a peak last month the case fatality rate (CFR) in those aged over 80 had dropped by more than 30% in England**
- The data suggests that vaccines are working

HEALTH FOR ALL BY ALL
a call for solidarity and action

No-fault compensation scheme: Information, next steps

World Health Organization

Communication with all AMC countries early in February

- COVAX no-fault compensation (NFC) scheme is for AMC Participants
- Objective: No-fault lump-sum compensation (full and final settlement) for persons with SAE after a COVID-19 vaccine from COVAX Facility
- WHO will appoint administrators for the NFC scheme

➔ Countries to communicate point of contact (and supervisor) with COVAX by 12 Feb 2021 deadline

- (National EPI Manager)

HEALTH FOR ALL BY ALL a call for solidarity and action

SAE: Serious Adverse Event; AMC: Advance Market Commitment supported with Official Development Assistance

Supply and procurement

Supply: >80M doses of AZ/SK Bio and AZ/SII available in Q1 2021 (Globally)

- ~60M doses AZ/SII and ~25M doses AZ/SK Bio
- 23M doses available in February

Three conditions for countries

1. Vaccine allocated to the country
2. Indemnification and liability agreement signed
3. Regulatory approval and import authorization

Procurement channels:

AMC countries: UNICEF Supply Division will place Purchase Order (PO)

Self financing countries:

- Procuring through UNICEF: Cost-estimate sent to country after allocation, cash to be provided in advance
- Self procuring: Direct engagement with the supplier

HEALTH FOR ALL BY ALL a call for solidarity and action

Action points for countries

- Indemnification & Liability (I&L) agreement
  - AMC countries: Give COVAX green light re: I&L agreement template shared 5 Feb
  - FSF countries: reach out to manufacturers and sign the I&L agreement
- Confirm regulatory approval for the indicative vaccine(s)
- Secure import license for the indicative vaccine(s)
- **Develop plans for refugees, migrants, persons of concerns and living in Fragile, Conflict and Vulnerable [FCV] contexts**
- Specific action point for AMC countries
  - Share point of contact details with COVAX for no fault compensation scheme
  - Update National Development and Vaccine use Plan (NDVP)
    - Address comments from the Regional Review Committee (if any)
    - Specify and quantify vaccination targets and strategies to reach the next 17%, including FCV
    - Plan cold chain required to reach the next 17%, including FCV

HEALTH FOR ALL BY ALL a call for solidarity and action

AMC: Advance Market Commitment supported with Official Development Assistance
FSF: Fully Self Financing

Summary

- More and more vaccines available, with first documentation of effectiveness in the real world
- Progress on the regulatory front, including WHO emergency use listing for AstraZeneca
- WHO recommends AstraZeneca vaccine for adults above 18 years of age
  - Even when variants are reported
- COVAX process coming together, with improved communication and partners engagement

Additional slides

World Health Organization